Delivering guideline-directed medical therapy for heart failure with reduced ejection fraction as an over-encapsulated polypill: rationale and protocol for the COMBO-HF-X pilot crossover randomised clinical trial.

Saved in:
Bibliographic Details
Title: Delivering guideline-directed medical therapy for heart failure with reduced ejection fraction as an over-encapsulated polypill: rationale and protocol for the COMBO-HF-X pilot crossover randomised clinical trial.
Authors: DeJong C; Cardiology Section, VA Palo Alto Health Care System, Palo Alto, California, USA colette.dejong@va.gov.; Division of Cardiology, Stanford University School of Medicine, Stanford, California, USA., Durstenfeld MS; Division of Cardiology, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, California, USA., Davis JD; Division of Cardiology, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, California, USA., Wang CS; Division of Pharmacy, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California, USA., Riley ED; Division of HIV, Infectious Disease, and Global Medicine, University of California San Francisco, San Francisco, California, USA., Huffman MD; Cardiovascular Division and Global Health Center, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.; The George Institute for Global Health, Sydney, New South Wales, Australia., Hickey MD; Division of HIV, Infectious Disease, and Global Medicine, University of California San Francisco, San Francisco, California, USA., Shade SB; Division of Infectious Disease and Global Epidemiology, Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA., Chen JC; Cardiovascular Division, Washington University in St Louis School of Medicine, St Louis, Missouri, USA., Kazi DS; Richard A. and Susan F. Smith Center for Outcomes Research, Division of Cardiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Grochowski J; Division of HIV, Infectious Disease, and Global Medicine, University of California San Francisco, San Francisco, California, USA., Steward WT; Division of Prevention Science, Department of Medicine, University of California San Francisco, San Francisco, California, USA., Zier LS; Division of Cardiology, Zuckerberg San Francisco General Hospital, University of California San Francisco, San Francisco, California, USA.; Division of Clinical Informatics and Digital Transformation, University of California San Francisco, San Francisco, California, USA., Moreau N; Division of Pharmacy, Zuckerberg San Francisco General Hospital and Trauma Center, San Francisco, California, USA., Sandhu AT; Cardiology Section, VA Palo Alto Health Care System, Palo Alto, California, USA.; Division of Cardiology, Stanford University School of Medicine, Stanford, California, USA., Heidenreich PA; Cardiology Section, VA Palo Alto Health Care System, Palo Alto, California, USA.; Division of Cardiology, Stanford University School of Medicine, Stanford, California, USA., Agarwal A; Cardiovascular Division and Global Health Center, Washington University in St Louis School of Medicine, St Louis, Missouri, USA., Hsue PY; Division of Cardiology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, California, USA.
Source: BMJ open [BMJ Open] 2025 Mar 21; Vol. 15 (3), pp. e093663. Date of Electronic Publication: 2025 Mar 21.
Publication Type: Clinical Trial Protocol; Journal Article
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2044-6055
DOI:10.1136/bmjopen-2024-093663